Kodiak Sciences Q3 net loss widens

Kodiak Sciences

13/11/2025 21:30

Overview

Kodiak Sciences reports Q3 net loss of $61.5 mln, increased from $43.9 mln last year

R&D expenses rise to $50.5 mln in Q3, driven by active clinical studies

Kodiak ends Q3 with $72 mln in cash, down from $168 mln last year

Outlook

Kodiak expects topline data for tarcocimab's Phase 3 GLOW2 study in 1Q 2026

Topline data for KSI-501's Phase 3 DAYBREAK study expected in 3Q 2026

Kodiak anticipates topline data for KSI-101's Phase 3 PEAK study in 4Q 2026

Result Drivers

CLINICAL STUDY PROGRESS - Increased R&D expenses driven by active DAYBREAK and PEAK/PINNACLE studies and manufacturing activities

RAPID ENROLLMENT - Phase 3 PEAK and PINNACLE studies of KSI-101 enrolling faster than expected

MECHANISM VALIDATION - KSI-101 mechanism of action validated by scientific community, enhancing clinical effect

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$1.16
Q3 Net Income
-$61.46 mln
Q3 Basic EPS
-$1.16
Q3 Operating Expenses
$62.35 mln
Q3 Operating Income
-$62.35 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Kodiak Sciences Inc is $17.00, about 19.1% below its November 12 closing price of $20.25

Press Release: ID:nPn1Lt6j0a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)